亚太药业
(002370)
| 流通市值：28.04亿 | | | 总市值：28.04亿 |
| 流通股本：7.46亿 | | | 总股本：7.46亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 776,793,031.37 | 743,850,694.68 | 689,103,730.3 | 686,352,627.85 |
| 应收票据及应收账款 | 89,445,228.74 | 95,309,526.3 | 80,215,026.89 | 74,656,806.86 |
| 应收账款 | 89,445,228.74 | 95,309,526.3 | 80,215,026.89 | 74,656,806.86 |
| 应收款项融资 | 32,410,018.25 | 16,367,501.71 | 19,738,669.93 | 26,326,103.71 |
| 预付款项 | 1,397,897.48 | 3,099,599.07 | 2,014,727.9 | 1,455,733.74 |
| 其他应收款合计 | 14,827,334.18 | 16,142,967.87 | 33,141,675.13 | 29,876,254.72 |
| 存货 | 80,217,397.39 | 70,128,529.14 | 69,366,932.16 | 81,522,997.59 |
| 其他流动资产 | 9,538,216.27 | 10,261,570.55 | 10,973,902.12 | 11,652,069.5 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 1,004,629,123.68 | 955,160,389.32 | 904,554,664.43 | 911,842,593.97 |
| 非流动资产: | | | | |
| 其他非流动金融资产 | 36,747,170.59 | 38,485,729.8 | 38,796,613.03 | 34,985,199.55 |
| 投资性房地产 | - | - | 619,657.62 | 628,419 |
| 固定资产 | 330,860,741.29 | 338,078,979.81 | 344,271,783.4 | 350,846,303.19 |
| 在建工程 | 297,500 | 29,220 | 979,260.02 | 798,888.34 |
| 无形资产 | 52,746,936.45 | 54,195,160.47 | 54,912,837.32 | 56,343,911.32 |
| 开发支出 | 15,618,009.04 | 15,618,009.04 | 13,637,951.45 | 12,996,442.01 |
| 长期待摊费用 | 150,660 | 200,880 | 251,100 | 301,320 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 436,421,017.37 | 446,607,979.12 | 453,469,202.84 | 456,900,483.41 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 1,441,050,141.05 | 1,401,768,368.44 | 1,358,023,867.27 | 1,368,743,077.38 |
| 流动负债: | | | | |
| 短期借款 | 30,026,583.33 | 30,055,583.33 | - | - |
| 应付票据及应付账款 | 66,631,806.78 | 45,765,335.37 | 34,906,289.49 | 44,182,363.87 |
| 其中：应付票据 | 18,538,318.7 | - | - | - |
| 应付账款 | 48,093,488.08 | 45,765,335.37 | 34,906,289.49 | 44,182,363.87 |
| 预收款项 | - | - | 6,880.78 | 27,522.97 |
| 合同负债 | 6,315,614.21 | 2,233,319.42 | 2,355,854.71 | 2,395,994.35 |
| 应付职工薪酬 | 6,413,471.04 | 11,869,414.21 | 8,528,257.23 | 8,487,351.57 |
| 应交税费 | 998,567.03 | 5,370,960.37 | 1,776,172.29 | 3,944,243.26 |
| 其他应付款合计 | 48,882,214.68 | 19,154,466.61 | 31,651,077.78 | 30,644,964.33 |
| 一年内到期的非流动负债 | 270,459,833.1 | 301,697,044.76 | 606,594,485.67 | 645,564,136.37 |
| 其他流动负债 | 821,029.85 | 290,331.53 | 306,261.11 | 311,479.27 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 430,549,120.02 | 416,436,455.6 | 686,125,279.06 | 735,558,055.99 |
| 非流动负债: | | | | |
| 预计负债 | 4,933,357.37 | 4,933,357.37 | 38,043,600 | 38,043,600 |
| 递延收益 | 4,060,824.34 | 4,360,565.93 | 4,660,307.45 | 4,960,048.97 |
| 递延所得税负债 | 3,645,644.31 | 3,856,985.92 | 3,768,148.71 | 3,196,436.69 |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 12,639,826.02 | 13,150,909.22 | 46,472,056.16 | 46,200,085.66 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 443,188,946.04 | 429,587,364.82 | 732,597,335.22 | 781,758,141.65 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 739,627,912 | 728,586,186 | 625,244,402 | 609,180,082 |
| 其他权益工具 | 56,321,681 | 63,352,923.19 | 129,159,197.14 | 139,388,669.86 |
| 资本公积 | 1,936,419,835.7 | 1,906,946,915.41 | 1,635,427,265.69 | 1,593,885,812.32 |
| 其他综合收益 | - | 0 | - | - |
| 盈余公积 | 60,559,514.31 | 60,559,514.31 | 60,559,514.31 | 60,559,514.31 |
| 未分配利润 | -1,795,067,748 | -1,787,264,535.29 | -1,824,963,847.09 | -1,816,029,142.76 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 997,861,195.01 | 972,181,003.62 | 625,426,532.05 | 586,984,935.73 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 997,861,195.01 | 972,181,003.62 | 625,426,532.05 | 586,984,935.73 |
| 负债和股东权益合计 | 1,441,050,141.05 | 1,401,768,368.44 | 1,358,023,867.27 | 1,368,743,077.38 |
| 公告日期 | 2025-04-30 | 2025-04-25 | 2024-10-31 | 2024-08-24 |
| 审计意见(境内) | | 标准无保留意见 | | |